Vertex Pharmaceuticals, Inc. (NASDAQ:VRTX)
| CAPS Rating |
|
|---|---|
| Open | $36.83 |
| Previous Close | $37.04 |
| Daily Range | $36.06 - $37.00 |
| 52-Week Range | $26.50 - $58.87 |
| Market Cap | $7.52B |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 1,763,933 |
| Average Daily Volume | 0 |
VRTX
VS S&P 500 (SPY)
How do you think VRTX will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
VRTX Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
VRTX News and Commentary
- A Look at Vertex's Intangibles – The Motley Fool
- Curing Diseases Makes For a Bad Business Model – The Motley Fool
- Incivek Catalyst at Play for Vertex - Analyst Blog – NASDAQ
- 4th UPDATE: Merck Swings To 4Q Profit; Sales Up 4% – SmartMoney
- 3rd UPDATE: Merck Swings To 4Q Profit; Sales Up 4% – SmartMoney
- 2nd UPDATE: Merck Swings To 4Q Profit On Fewer Charges; Sales Up 2% – SmartMoney
- UPDATE: Merck Swings To 4Q Profit On Fewer Charges; Sales Up 2% – SmartMoney
- New CEO = Dendreon Takeover Target? – The Motley Fool
- Maximum Market: $2.9 Billion, For Now – The Motley Fool
- 3 Stocks to Get on Your Watchlist – The Motley Fool
- Company News for February 1, 2012 - Corporate Summary – NASDAQ
- Vertex Pharmaceuticals Shares Popped: What You Need to Know – The Motley Fool
- Vertex Announces Key 2012 Business Objectives as Company Prepares for Planned Global Launch of KALYDECO in Cystic Fibrosis – Blog at The Motley Fool
- FDA Approves KALYDECO™ (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis – Blog at The Motley Fool
- Celldex has potential to have a blockbuster Breast Cancer Drug – Blog at The Motley Fool
- 3 Biotech Buyout Candidates for 2012 – The Motley Fool
- Under $40 with over $4 eps in 2012 forecast – Blog at The Motley Fool
- Could These Huge Health-Care Buyouts Continue? – The Motley Fool
- The Zacks Analyst Blog Highlights: Gilead Sciences, Bristol-Myers Squibb, Inhibitex, Vertex Pharmace – NASDAQ
- Gilead Clinches Pharmasset Buy - Analyst Blog – NASDAQ
RSS Headlines
Fool UK
